Verrica Pharmaceuticals (VRCA) Amortizatization of Intangibles (2018 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Amortizatization of Intangibles of $100000.0 for Q1 2026, up 19.05% year-over-year from $84000.0 in Q1 2025, and up 534.78% quarter-over-quarter from -$23000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 19.05% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $246000.0 (down 76.48% YoY), while the FY2025 annual figure was $352000.0, down 43.13% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $100000.0, up from -$23000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $619000.0 in Q4 2024, with the low at -$49000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $86000.0 (2025), against an average of $103571.4.
- The sharpest annual moves came in 2022 and 2024: Amortizatization of Intangibles plunged 450.0% in 2022, then jumped 2995.0% in 2024.
- Verrica Pharmaceuticals' Amortizatization of Intangibles stood at $97000.0 in 2022, then plunged by 79.38% to $20000.0 in 2023, then surged by 2995.0% to $619000.0 in 2024, then tumbled by 103.72% to -$23000.0 in 2025, then soared by 534.78% to $100000.0 in 2026.
- Business Quant data shows VRCA's Amortizatization of Intangibles at $100000.0 in Q1 2026, -$23000.0 in Q4 2025, and $88000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 113,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113,000.00 |
| Jun 30, 2026 | 113,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -23,000.00 |
| Dec 31, 2025 | -23,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 84,000.00 |
| Mar 31, 2025 | 84,000.00 |
| Dec 31, 2024 | 619,000.00 |
| Dec 31, 2024 | 619,000.00 |
| Sep 30, 2024 | 187,000.00 |
| Sep 30, 2024 | 187,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |